Dykstra v. Wyeth Pharmaceuticals, Inc.

454 F. App'x 20
CourtCourt of Appeals for the Second Circuit
DecidedJanuary 4, 2012
Docket10-4117-cv
StatusUnpublished
Cited by3 cases

This text of 454 F. App'x 20 (Dykstra v. Wyeth Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dykstra v. Wyeth Pharmaceuticals, Inc., 454 F. App'x 20 (2d Cir. 2012).

Opinion

SUMMARY ORDER

Plaintiff-appellant Joseph Dykstra (“Dykstra”) appeals from a judgment entered September 16, 2010, granting the *21 motion for summary judgment of defendant-appellee Wyeth Pharmaceuticals (“Wyeth”). The District Court granted Wyeth’s motion solely on the basis that the applicable statute of limitations had expired before Dykstra filed his complaint. We assume the parties’ familiarity with the underlying facts, procedural history of the case, and the issues on appeal.

Dykstra was employed by Wyeth as an aseptic setup worker, with responsibilities including setting up and maintaining equipment used to fill biological syringes. As a union employee, his employment was governed by the terms of a Collective Bargaining Agreement (“CBA”) between Wyeth and the International Chemical Workers Union, Local 143c. Pursuant to the CBA, “[a]n employee whose action appears to necessitate his/her discharge shall first be suspended subject to discharge and so be informed. If no request for grievance procedure is made within seven (7) days, the action taken by the Company shall become final.”

On or about March 29, 2007, Wyeth learned that Dykstra had signed the initials of other employees on documents that Wyeth maintained as part of its obligation, as a manufacturer regulated by the Food and Drug Administration (“FDA”), to document its compliance with FDA requirements for good manufacturing practices. Section IV of the Wyeth Manufacturing Employee Manual provides that “[ijntentional falsification of a cGMP document [that is, a document that confirms compliance with FDA good manufacturing practices] by any employee will result in immediate suspension pending discharge!” On April 17, 2007, Dykstra’s supervisor issued him a notice of suspension pending discharge for falsifying cGMP documents. He was immediately escorted from the facility and relieved of his facility entrance card and employee badge. Dykstra’s pay was halted the same day.

Within the seven days allotted by the CBA, Dykstra, through his union, filed a grievance. A hearing was held on May 22, 2007 before the Associate Director of Labor Relations. By letter of June 11, 2007, the Associate Director advised Dykstra that he had been found responsible for falsifying cGMP documents and therefore his employment was terminated effective June 11, 2007.

On June 6, 2008, Dykstra filed a complaint in the Supreme Court of the State of New York, Rockland County, alleging that he was terminated in retaliation for reporting safety violations to a supervisor. 1 This termination, he claimed, violated the New York “whistle-blower statute,” N.Y. Labor Law § 740, which prohibits an employer from taking “any retaliatory personnel action against an employee” because the employee discloses to a supervisor or public body an activity, policy or practice of the employer that violates a “law, rule or regulation which violation creates and presents a substantial and specific danger to the public health or safety, or which constitutes health care fraud.” N.Y. Lab. Law § 740(2)(a). Dykstra alleged that he was discharged in retaliation for reporting to a supervisor in March 2007 that he had observed two maintenance workers in a “clean room” failing to comply with sterilization procedures and lacking proper certification, in violation of Wyeth policies. 2

*22 Section 740 permits an employee who believes he has been retaliated against in violation of the statute to “institute a civil action ... within one year after the alleged retaliatory personnel action was taken.” Id. The dispositive question before the District Court, therefore, was whether Dykstra’s cause of action accrued on April 17, 2007, when he was notified of his suspension pending discharge, or June 11, 2007, the effective date of his termination. The District Court concluded that his cause of action accrued on April 17, 2007, and that his complaint, filed June 6, 2008, was thus barred by the one-year statute of limitations. It accordingly granted Wyeth’s motion for summary judgment.

“We review de novo the district court’s grant of summary judgment, drawing all factual inferences in favor of the non-moving party.” Paneccasio v. Unisource Worldwide, Inc., 582 F.3d 101, 107 (2d Cir.2008). “Summary judgment is proper only when, construing the evidence in the light most favorable to the non-movant, ‘there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law.’ ” Doninger v. Niehoff, 642 F.3d 334, 344 (2d Cir.2011) (quoting Fed.R.Civ.P. 56(a)). Having conducted a de novo review of the record and considered the parties’ submissions, we agree with the District Court that Dykstra’s claim is barred by the statute of limitations. See Dykstra v. Wyeth Pharmaceuticals, Inc., No. 08-CV-07432 (S.D.N.Y. Sept.16, 2010).

In arriving at its conclusion that Dykstra’s cause of action accrued on April 17, 2007, when he was notified of his “suspension pending discharge,” the District Court relied on case law interpreting statutes of limitation governing comparable federal employment discrimination laws. Though Dykstra, too, relied on these federal cases below, he now argues that we should look exclusively to New York state law.

On appeal, Dykstra has cited one New York case, Dobson v. Loos, 277 A.D.2d 1013, 716 N.Y.S.2d 220 (4th Dep’t 2000), which, he contends, provides an interpretation of § 740’s statute of limitations that supports his position. The Appellate Division held in Dobson that where a Sheriffs Department took “active and extraordinary measures to preclude [the plaintiffs] appointment as Lieutenant during the life of [a] preferred eligibility list until its expiration”—including repeatedly promoting others ahead of the plaintiff—this constituted a continuing violation such that the plaintiff could bring a cause of action within one year of the expiration of the eligibility list. Id. at 221.

The ongoing and repeated failure to promote the plaintiff in Dobson is entirely different from Dykstra’s termination. As noted above, the CBA governing Dykstra’s employment with Wyeth effectively prohibits Wyeth from terminating an employee without first suspending him pending a grievance proceeding: “An employee whose action appears to necessitate his/ her discharge shall first be suspended subject to discharge and so be informed.” Furthermore, if the employee does not request a grievance proceeding within seven days of this notification, “the action taken by the Company shall become final.” (Emphases added.) In other words, no separate personnel action is required to terminate the employee once notice of suspension pending discharge is provided. The actual termination, therefore, flows as an inevitable consequence from the notice of suspension, and only the potential intervening act of the grievance hearing officer can separate the two. Under these cir *23

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
454 F. App'x 20, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dykstra-v-wyeth-pharmaceuticals-inc-ca2-2012.